AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01722084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theory of planned behaviour (TPB) and social cognitive theory (SCT).
Description: TPB is appropriate to influence adolescents' behaviour related to the use of contraceptive methods and their health/information seeking behaviour. The SCT helped to find out strategies to improve communication about sexuality, to promote openness towards adolescents' sexuality among parents, community members and health providers and for health providers to adopt a more adolescent friendly attitude.The development of the strategies in the different countries is a dynamic process that is continuously being adapted. The target groups were driving the process of identifying, selecting and implementing interventions. Therefore, local institutions were involved in the intervention. Attention was paid to ensure that the interventions were in line with the existing local structures/policies and reinforce the local health system.Primary health care services had a key role in the interventions. Gender was a transversal topic throughout the intervention process.
Study NCT01785693 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: levobupivacaine, clonidine
Study NCT01631981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL2001 + Primolut-Nor 5
Description: PGL2001(estradiol sulfamate, E2MATE, ZK190628), Tablets, 1mg. 4 mg weekly for 4 weeks followed by 2mg weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg. Once daily for 16 weeks plus during follow-up.
Study NCT01631981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Primolut-Nor 5
Description: Placebo, Tablets.4 tablets weekly for 4 weeks followed by 2 tablets weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg.Once daily for 16 weeks plus during follow-up.
Study NCT01816282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evicel
Description: Evicel (5ml) is sprayed over the soft tissue after the implant of prosthetic components and before wounding closure
Study NCT03895541 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SuperSonic image
Description: 3 examen performed assessed to compared evaluation type: Cardiac magnetic resonance imaging, standard ultrasound imaging and ultrafast imaging
Study NCT00950105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPSI-2364 or placebo
Description: Single, oral dose of CPSI-2364 or placebo
Study NCT03254628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentor
Description: A birth attendant in the facility is designated as a clinical mentor and encouraged to lead simulator-based practice sessions in the facility after training day.
Study NCT03254628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone
Description: District trainers telephone clinical mentors and encourage them to lead practice sessions.
Study NCT03254628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin and misoprostol
Description: This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.
Study NCT03254628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin and misoprostol
Description: This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.
Study NCT03254628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Newborn bag and mask
Description: All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care
Study NCT03254628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Newborn bag and mask
Description: All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care
Study NCT01234480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD SurePath Plus Pap test
Description: BD SurePath Plus Pap test
Study NCT01234480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD SurePath Pap test
Description: BD SurePath Plus Pap test
Study NCT02531204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP1585
Description: oral
Study NCT02531204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral
Study NCT04316065 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: YHP1906
Description: YHP1906 Tab. 5 mg
Study NCT04316065 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: YHR1902
Description: Comparator. YHR1902 Tab. 5 mg
Study NCT00589251 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: penicillin skin test
Description: Prick skin tests will be performed on the volar surface of the forearm with each penicilloate and control reagents. The skin test sites will be examined at 15 minutes. A positive test result is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. Patients with negative prick test results to penicillin will undergo intradermal testing.~Intradermal skin tests will be performed on the volar surface of the forearm. The test reagents will be injected intradermally to produce an initial wheal of 2x2 mm. The skin test sites will be examined at 15 minutes. A positive intradermal test is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. In order to ensure patient safety, we will consider using an end point titration technique.
Study NCT02080234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GELOX
Description: gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
Study NCT02080234 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IFRT
Description: IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions
Study NCT01540240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Low dosage AZT arm: AZT 200 mg/3TC 150 mg(zidovudine 100 mg 2 caps/lamivudine 150 mg 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
Study NCT01540240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
Study NCT00003211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT03934203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet
Study NCT00003211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Study NCT00003211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00003211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00003211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00003211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00003211 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01234480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colposcopy with biopsy/ECC
Description: Colposcopy with biopsy/ECC for subjects with 1)BD SurePath Pap NILM, but HPV positive, or 2) BD SurePath Plus Pap test result of ASC-US or higher 3)BD SurePath Pap ASC-US or higher
Study NCT01234480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPV DNA test
Description: digene HC2 HPV DNA test
Study NCT02104323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostatin
Description: Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.
Study NCT03835013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Intravenous infusion of 0.9% saline
Study NCT03835013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline 0.9%
Description: Intravenous infusion of 0.9% saline
Study NCT03835013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon (25ng/kg/min)
Description: Intravenous infusion of glucagon 25ng/kg/min
Study NCT03835013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon (50ng/kg/min)
Description: Intravenous infusion of glucagon 50ng/kg/min
Study NCT03835013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Intravenous infusion of Exenatide (loading 50ng/min for 30 minutes followed by 25ng/min for 30 minutes
Study NCT01002898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir soft gel capsule
Description: Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
Study NCT02597491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TLC monthly
Description: Tobacco longitudinal care monthly
Study NCT02740699 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: Participants will receive 20-40 mg once daily
Study NCT02740699 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: Participants will receive 40-80 mg once daily.
Study NCT02740699 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Cardiac Computed Tomography (CT)
Description: Cardiac CT angiography (CCTA) provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Performed at baseline, 12 months 24 months, and 36 months.
Study NCT02597491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TLC quarterly
Description: Tobacco longitudinal care quarterly
Study NCT02597491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MTM
Description: Medication management therapy
Study NCT02597491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 week assessment
Description: 4 week assessment
Study NCT02597491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 8 week assessment
Description: 8 week assessment
Study NCT02740699 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Cardiac Magnetic Resonance Image (MRI)
Description: Provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Cardiac MRI may be performed at baseline, and 24 months (optional).
Study NCT01586650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: The intervention comprises fifty minutes of walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
Study NCT01911078 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal Denervation
Description: Renal artery ablation with the EnligHTN™ Renal Denervation System.
Study NCT01586650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.
Study NCT01586650 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stretching exercises
Description: Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.
Study NCT01220713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 1.5 atm abs oxygen equivalent of 75% oxygen (balance 25% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
Study NCT01220713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 2.0 atm abs oxygen equivalent of 100% oxygen (no nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
Study NCT03040739 — intervention group
Intervention type: OTHER
Intervention: use of O'ARM imaging system
Description: use of O'ARM imaging system
Study NCT00720356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10mg/kg administered intravenously every 2 weeks
Study NCT00720356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 150 mg/daily orally
Study NCT01220713 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: sham--air equivalent of 10.5% oxygen (balance 89.5% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
Study NCT02241421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Study NCT02241421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Study NCT02241421 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03014180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Clinic LVAT
Description: Algorithm offers automatic threshold measurement of differents vectors of left ventricular stimulation.
Study NCT04514536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health monitors
Description: * The connected scale (iHealth HS2) measures weight from 5 to 180kg and BMI.~* The connected actimeter (iHealth AM4) monitors activity (number of steps, distance, calories), sleep (automatic sleep recognition, effective sleep time, number of awakenings) and swimming (automatic activity recognition, session duration, swim type recognition and number of laps).~* The connected blood pressure monitor (iHealth Track KN-550BT)is a medical device that measures blood pressure and pulse rate.~* The activity monitor (manufactured by RF Track) consists of a housing that can be positioned as a pendant or at the hip. It includes an accelerometer, gyroscope, magnetometer, barometer, radio transceiver, and led. The sensor records the raw signals.~* The touchpad allows the subject to connect to the Calliope app. This app allows the data recovery, storage, analysis, visualization, and all the required settings for the platform to work together.
Study NCT02409147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Transplant
Description: Surgical implantation of a deceased donor uterus, induction therapy with thymoglobulin or basiliximab, maintenance immunosuppression with Prograf, Cellcept, and Prednisone. Anti-infective treatment with Bactrim and Valcyte and Nystatin. Anti-platelet therapy with aspirin. IVF per standard protocol. At time of birth: ceasarean section. Ultimately, transplant hysterectomy.
Study NCT04189796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Cheese
Description: Daily oral intake of cheese
Study NCT04189796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cheese
Description: Daily oral intake of cheese
Study NCT04651764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ColubrisMX Endoluminal Surgical (ELS) System
Description: Robotically assisted transanal endoluminal resection of rectal lesion using the ColubrisMX Endoluminal Surgical (ELS) System
Study NCT03519841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P0.1
Description: Investigational Medical Device collecting spectral Raman data from tissue.
Study NCT04356209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-PRO Intervention
Description: Statements of symptoms and patients' health status (PROs) will be collected via a web interface, including access and use in patients with burden symptoms.~The platform will include four items concerning 7 side effects of fibrosis of grade > 2 in breast cancer. Patients will be encouraged to evaluate on a 5-point Likert scale the frequency, the intensity and the repercussions on the daily life of some symptoms during the last 7 days, in particular on:~* general pain~* anxiety~* sadness~* texture of the treated breast~* Patients will also be invited to express themselves on the severity of two other symptoms of their choice, to their worst degree, by listing and rating them on a 5-point scale ranging from None to Very severe Finally, the aesthetic impact will be evaluated by patients on a visual analogue scale (VAS) of 0 to 100mm
Study NCT03740399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: Investigators will perform spinal anesthesia for section
Study NCT03000556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% Sodium Hyaluronate Eye Drop
Description: The patients need to use 0.3% Sodium Hyaluronate Eye Drop for 3 month.
Study NCT03313635 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Men presenting with low-T
Description: Evaluation of prealbumin levels.
Study NCT04248712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 40 mg tab twice daily by mouth for 12 week duration
Study NCT04248712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: 10 mg tab once daily by mouth for 12 week duration
Study NCT04248712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains no active ingredient
Study NCT04013269 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb-Therapy
Description: Additional use of Cytosorb-Adsorber in patients with septic shock and need for continuous renal replacement therapy
Study NCT01966354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Internal jugular venous approach
Description: The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.~In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane).
Study NCT01322724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warm vs Cool water
Description: Body vs Room temperature water used during insertion of colonoscopy
Study NCT01322724 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Warm vs Cool water
Description: Body vs Room temperature water used during insertion of colonoscopy
Study NCT00936637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed infant formula
Study NCT04098887 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lattice stereotactic body radiation therapy
Description: For Lattice SBRT, the daily prescription dose will be 20 Gy to be delivered to the PTV_2000 with a simultaneous integrated boost of 66.7 Gy to be delivered to the PTV_6670 over 5 fractions (4 Gy and 13.2 Gy to the PTV_2000 and PTV_6670, respectively).
Study NCT03138317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: This group will receive a knee injection with 6 ml of platelet rich plasma (PRP)
Study NCT03138317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma
Description: This group will receive a knee injection with 6 ml of plasma.
Study NCT01948466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commercials
Description: These commercials will display child actors and try to grab the attention of the 3rd - 5th grade viewers. They will be humorous, fun, and call the viewer to action so the students will feel they should consume fruits and vegetables like the children in the commercials.
Study NCT03138317 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive a knee injection with 6 ml saline solution.
Study NCT03910725 — intervention group
Intervention type: OTHER
Intervention: Electrocardiographic imaging
Description: ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
Study NCT04356209 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pravastatin
Description: All patients will take Pravastatin 40 mg per day (From Day 0 to Month 12).
Study NCT04356209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: All patients will take Pravastatin 40 mg per day (From Day 0 to Month 12).
Study NCT00671398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally for one night only.
Study NCT00671398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 16 mg, tablets, orally for one night only
Study NCT00671398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally for one night only
Study NCT00436020 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Transcranial Magnetic Stimulation
Study NCT00436020 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham TMS
Description: Sham Transcranial Magnetic Stimulation
Study NCT02057367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scalp block with 0.5% plain Marcaine
Description: Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.
Study NCT01282255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC109-0012
Description: The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)